ERBB2 and breast cancer: This study, which included 6268 patients with MBC and 118,817 patients with early-stage breast cancer, found 3-year survival rates of 47.6 % for patients with HER2-positive MBC and 44.8 % for patients with HER2-negative MBC [20].